- Home
- ALTS vs IGC Comparison
ALTS vs IGC Comparison
Compare ALTS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- IGC
- Stock Information
- Founded
- ALTS 1976
- IGC 2005
- Country
- ALTS United States
- IGC United States
- Employees
- ALTS N/A
- IGC N/A
- Industry
- ALTS
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- ALTS
- IGC Health Care
- Exchange
- ALTS NYSE
- IGC Nasdaq
- Market Cap
- ALTS 26.0M
- IGC 23.8M
- IPO Year
- ALTS N/A
- IGC N/A
- Fundamental
- Price
- ALTS $1.80
- IGC $0.37
- Analyst Decision
- ALTS
- IGC Strong Buy
- Analyst Count
- ALTS 0
- IGC 2
- Target Price
- ALTS N/A
- IGC $3.63
- AVG Volume (30 Days)
- ALTS 218.9K
- IGC 681.3K
- Earning Date
- ALTS 11-12-2024
- IGC 11-11-2024
- Dividend Yield
- ALTS N/A
- IGC N/A
- EPS Growth
- ALTS N/A
- IGC N/A
- EPS
- ALTS N/A
- IGC N/A
- Revenue
- ALTS $2,169,000.00
- IGC $1,062,000.00
- Revenue This Year
- ALTS N/A
- IGC N/A
- Revenue Next Year
- ALTS N/A
- IGC $13.57
- P/E Ratio
- ALTS N/A
- IGC N/A
- Revenue Growth
- ALTS N/A
- IGC N/A
- 52 Week Low
- ALTS $0.22
- IGC $0.25
- 52 Week High
- ALTS $5.26
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- ALTS 41.37
- IGC 50.23
- Support Level
- ALTS $1.70
- IGC $0.35
- Resistance Level
- ALTS $1.89
- IGC $0.48
- Average True Range (ATR)
- ALTS 0.15
- IGC 0.03
- MACD
- ALTS -0.02
- IGC 0.00
- Stochastic Oscillator
- ALTS 19.61
- IGC 27.00
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. It is providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment and safe-keeping of digital assets. The company product include ALT 5 Prime is an electronic over-the-counter trading platform and ALT 5 Pay crypto payment processor.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.